Tagrisso

Active Ingredient(s): Osimertinib
FDA Approved: * November 13, 2015
Pharm Company: * ASTRAZENECA PHARMS
Category: Cancer

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".



Tagrisso Overview

Osimertinib (previously known as mereletinib; trade name Tagrisso)[2][3] is a medication used to treat non-small-cell lung carcinomas with a specific mutation.[4][5] It is a third-generation epidermal growth factor receptor tyrosine kinase inhibitor. Developed by AstraZeneca, the medication was approved as a cancer treatment in 2017 by both the Food and Drug Administration and the European Commission. Contents 1 Medical uses...

Read more Tagrisso Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Osimertinib

Recent Tagrisso Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Osimertinib
  • Tablet: 40mg, 80mg
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Tagrisso: (2 results)

Sorted by National Drug Code
  • 0310-1349 Tagrisso 40 1/1 Oral Tablet, Film Coated by Astrazeneca Pharmaceuticals Lp
  • 0310-1350 Tagrisso 80 1/1 Oral Tablet, Film Coated by Astrazeneca Pharmaceuticals Lp

Other drugs which contain Osimertinib or a similar ingredient: (1 result)






Note: All times displayed are GMT - 7.

This information has been independently compiled and is for informational purposes only. It is not intended to be a substitute for medical advice from a qualified healthcare professional; nor is it intended to diagnose, treat, cure or prevent any disease. For more details please see the Medical Disclaimer. This page was last updated on 22 March 2019.

We are committed to your privacy.

Copyright © 2005-2019 All Rights Reserved. MedsChat® is a registered trademark of Limelight Innovations L.L.C. 9888 W Belleview Ave #5000, Denver, CO, 80123, USA